Nautilus Biotechnology, Inc

Newest shelf

$300.0M

S-3 of 2026-09-11. None sold under it to 2026-10-05. S-3 ↗

At the market

$125.0M

TD Securities (USA), agreement of 2026-09-11. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-07-28 is not read yet.

Cash

6.7 quarters

$84.0M on 2026-06-30 ÷ $12.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗